Xoma (XOMA) Price & Analysis

Compare

378 Followers

XOMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$18.35 - $35.00

Previous CloseN/A

Volume8.24K

Average Volume (3M)48.52K

Market Cap

$317.12M

Enterprise Value$374.82M

Total Cash (Recent Filing)$92.65M

Total Debt (Recent Filing)$114.45M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Aug 06, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding11,966,889

10 Day Avg. Volume27,841

30 Day Avg. Volume48,519

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.18

Enterprise Value/Revenue10.26

Enterprise Value/Gross Profit10.41

Enterprise Value/Ebitda-22.30

Forecast

1Y Price Target

$104.00

Price Target Upside292.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceXOMA reported 1Q25 revenue of $15.9M, 90% above the estimate of $8.2M.

Product DevelopmentXOMA stands to benefit significantly from the advancement of RZ358 (ersodetug), a Phase 3 asset being developed by Rezolute in congenital hyperinsulinism that could provide a meaningful royalty stream.

Strategic PartnershipsXOMA's strategy includes receiving 25% of royalties and milestones from partnered assets with major companies like Pfizer and Johnson & Johnson.

Bears Say

Competitive LandscapeThe competitive landscape in both ITP and IgA Nephropathy presents challenges, as multiple CD38-targeting therapies and other immune-modulating approaches are in development.

Regulatory EnvironmentThe risk of most-favored-nation pricing has potential implications for the entire biopharmaceutical sector.

Xoma News

Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR

XOMA Royalty (XOMA) and LAVA Therapeutics (LVTX) entered a definitive share purchase agreement whereby XOMA Royalty will acquire...

7d ago

LVTX

XOMA

HilleVax to be acquired by XOMA Royalty for $1.95 in cash per share plus CVR

HilleVax (HLVX) and XOMA Royalty (XOMA) announced today they have entered into a definitive merger agreement, whereby XOMA...

7d ago

HLVX

XOMA

XenoTherapeutics to acquire Essa Pharma

ESSA Pharma (EPIX) announced that it has entered into a definitive agreement with XenoTherapeutics under which Xeno will...

28d ago

EPIX

XOMA

Xoma’s Strategic Acquisitions and Royalty Expansion Drive Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Xoma and keeping the price target at...

6d ago

XOMA

Morning Movers: Li Auto lower following Q2 delivery guidance cut

Stock futures opened with a measured sense of optimism as the S&P 500 and Nasdaq inch closer to...

1M ago

AUB

Xoma to acquire Turnstone Biologics for $0.34 in cash per share

XOMA Royalty Corporation (XOMA) and Turnstone Biologics (TSBX) announced that they have entered into a definitive merger agreement,...

1M ago

TSBX

XOMA

Xoma Stockholders Approve Key Proposals at Annual Meeting

Xoma ( ($XOMA) ) has shared an announcement. During the Annual Meeting, Xoma‘s stockholders approved several key proposals,...

2M ago

XOMA

Positive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on XOMA stock, giving a Buy rating yesterday....

2M ago

XOMA

XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Xoma (XOMA – Research Report) and keeping...

2M ago

XOMA

Xoma purchases mezagitamab royalty, milestone rights for up to $30M

XOMA (XOMA) Royalty and BioInvent International announced XOMA Royalty has purchased the future mezagitamab royalty and milestone interests...

3M ago

XOMA

Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating

Leerink Partners analyst David Risinger maintained a Buy rating on Xoma (XOMA – Research Report) on May 15...

3M ago

XOMA

XOMA Royalty Reports Strong Q1 2025 Results

Xoma Corp. ( ($XOMA) ) has released its Q1 earnings. Here is a breakdown of the information Xoma...

3M ago

XOMA

Xoma reports Q1 EPS 6c, consensus (27c)

Reports Q1 revenue $15.9M, consensus $7.07M. “We are committed to generating value for shareholders through prudent cash deployment,...

3M ago

XOMA

XOMA Earnings this Week: How Will it Perform?

Xoma Corp. (XOMA) is scheduled to report 1st quarter earnings on 05/13/2025. Regarding Q1 estimates, Wall Street analysts...

3M ago

XOMA

XOMA FAQ

What was Xoma Corp’s price range in the past 12 months?

Xoma Corp lowest stock price was $18.35 and its highest was $35.00 in the past 12 months.

What is Xoma Corp’s market cap?

Xoma Corp’s market cap is $317.12M.

When is Xoma Corp’s upcoming earnings report date?

Xoma Corp’s upcoming earnings report date is Aug 06, 2025 which is 5 days ago.

How were Xoma Corp’s earnings last quarter?

Currently, no data Available

Is Xoma Corp overvalued?

According to Wall Street analysts Xoma Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xoma Corp pay dividends?

Xoma Corp does not currently pay dividends.

What is Xoma Corp’s EPS estimate?

Xoma Corp’s EPS estimate is -0.15.

How many shares outstanding does Xoma Corp have?

Xoma Corp has 11,966,889 shares outstanding.

What happened to Xoma Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Xoma Corp?

Currently, no hedge funds are holding shares in XOMA

Xoma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-3.42%

Trailing 12-Months

Asset Growth

-3.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xoma Corp

XOMA Corporation is a biotechnology company focused on discovering, developing, and commercializing therapeutic antibodies. The company operates in the biotechnology sector and primarily engages in the acquisition and licensing of antibody therapies. XOMA specializes in developing monoclonal antibodies that target a variety of diseases, and its core services include partnering with other pharmaceutical companies to advance these therapeutic candidates.

Xoma (XOMA) Earnings & Revenues

Historic Earnings Reports

XOMA Stock 12 Month Forecast

Average Price Target

$104.00

▲(292.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","105":"$105","39.75":"$39.8","61.5":"$61.5","83.25":"$83.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$104.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,39.75,61.5,83.25,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,30.864615384615384,36.95923076923077,43.05384615384615,49.14846153846154,55.24307692307693,61.33769230769231,67.43230769230769,73.52692307692308,79.62153846153846,85.71615384615384,91.81076923076922,97.90538461538462,{"y":104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,30.864615384615384,36.95923076923077,43.05384615384615,49.14846153846154,55.24307692307693,61.33769230769231,67.43230769230769,73.52692307692308,79.62153846153846,85.71615384615384,91.81076923076922,97.90538461538462,{"y":104,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,30.864615384615384,36.95923076923077,43.05384615384615,49.14846153846154,55.24307692307693,61.33769230769231,67.43230769230769,73.52692307692308,79.62153846153846,85.71615384615384,91.81076923076922,97.90538461538462,{"y":104,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.25,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.61,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >